⚠ New Science Could Rewrite the FieldModerate threat

Lilly's expertise is built on the current paradigms of drug discovery, and scientific revolutions can disrupt even the strongest incumbent. New modalities — gene editing, RNA therapies, cell therapies, AI-driven drug design — are reshaping how medicines are discovered and made, and a breakthrough from a nimble biotech or a rival applying new science could, in principle, leapfrog Lilly's franchises or render an approach it has mastered less relevant. The history of technology is full of leaders undone by a paradigm they did not own.

The danger is twofold. A scientific advance could produce a fundamentally better treatment for a condition Lilly dominates — a one-time gene therapy that cures what its drugs manage, say — undermining a franchise built on chronic treatment; or the locus of innovation could shift toward capabilities Lilly has not built, forcing it to acquire expensively or fall behind. Small, focused biotechs often pioneer the disruptive science, and while Lilly can buy them, bidding wars for breakthrough platforms are costly and not always won.

Lilly is itself investing heavily in new modalities, has the resources to acquire promising biotechs, and its therapeutic expertise transfers across scientific approaches — genuine defenses against disruption. But an owner should recognize that pharmaceutical leadership can be upended by science that emerges outside the incumbent's walls, that the pace of biological innovation is accelerating, that a company mastering today's paradigms is always exposed to tomorrow's, and that no amount of current dominance — not even a franchise growing 45% a year¹ — guarantees Lilly owns the breakthroughs that will define medicine a generation from now.